Sun-Novo(SH:688621) Ge Long Hui A P P·2026-01-16 13:19Core Viewpoint - The company, 阳光诺和, expects a net profit attributable to shareholders for the year 2025 to be between 191.05 million and 229.26 million yuan, representing a year-on-year growth of 7.69% to 29.23% [1] - The company anticipates a net profit excluding non-recurring gains and losses to be between 179.70 million and 215.64 million yuan, with a year-on-year growth of 8.84% to 30.61% [1] Group 1: Revenue and Profit Growth - The company has achieved steady growth in revenue and profit, driven by the deep layout of its innovative drug pipeline, realization of value from licensing collaborations, and synergistic support from its integrated service model [1] - The implementation of the "R&D services + pipeline cultivation + new quality industrial chain" strategy has provided solid support for business growth, leading to a steady improvement in the company's profitability [2] Group 2: Innovative Drug Pipeline - The company focuses on the research and development of innovative drugs with global independent intellectual property rights, constructing a pipeline matrix that includes over 20 first-class new drugs targeting major diseases such as cancer and pain [1] - Core pipelines like STC007 and STC008 have successfully entered critical clinical stages, generating stable income through R&D services and laying the foundation for long-term value release [1] Group 3: Licensing Collaborations - Licensing collaborations and revenue sharing have become key drivers of profit growth, with significant income generated from the licensing of pipelines such as STC007 and STC008, contributing to a high-margin revenue source [2] - The continuous optimization of the business structure is facilitated by these licensing agreements, enhancing the overall profitability of the company [2]